Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Relmada Therapeutics Initiates Phase 1 Study of REL-P11, a Low-Dose Psilocybin Formulation for Metabolic Disease Quiver Quantitative, Inc. - Thu Nov 14, 5:04PM CST

Relmada initiates Phase 1 study for REL-P11, a psilocybin formulation for metabolic disorders, with Phase 2a planned for 2025.Quiver AI SummaryRelmada Therapeutics has announced the initiation of dosing...

RLMD : 2.75 (-3.51%)
Healthcare - COVID-19 vaccines by HakanGERMAN via Pixabay
2 Breakout Biotech Stocks With CEO Insider Buying Barchart - Tue Sep 17, 2:09PM CDT

These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?

DYN : 29.73 (-0.87%)
RLMD : 2.75 (-3.51%)
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023 PR Newswire - Wed Oct 11, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.75 (-3.51%)
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit PR Newswire - Mon Oct 9, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.75 (-3.51%)
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress PR Newswire - Fri Oct 6, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.75 (-3.51%)
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder PR Newswire - Wed Sep 20, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.75 (-3.51%)
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.75 (-3.51%)
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results PR Newswire - Tue Aug 8, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.75 (-3.51%)
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 PR Newswire - Tue Aug 1, 2023

/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today...

RLMD : 2.75 (-3.51%)
RLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMD PR Newswire - Wed Jun 14, 2023

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of...

RLMD : 2.75 (-3.51%)

Barchart Exclusives

Recent Corn Rally Artificially Propped Up – What’s Next? Barchart - 16 minutes ago
Corn prices appeared to have finally found a bottom from the summer sell-off. Speculators were short the market in record numbers until late August, when they began buying back contracts, convincing some that the harvest seasonal low may be in. Then, exports increased in the last few weeks, and prices rallied more. While the bearish fundamentals of 1.9 billion carry-out and the massive amount of unpriced corn still linger, there isn’t much hope for a significant price rally yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot